Certara Appoints John Reynders as New Independent Board Member
Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, has appointed John Reynders, PhD, to its Board of Directors, effective October 15, 2024. Dr. Reynders brings over 25 years of experience in the pharmaceutical and tech industries, with expertise in artificial intelligence, data science, and life science.
Dr. Reynders' career highlights include serving as the founding CIO of Moderna, where he led data-sciences capabilities for mRNA therapy design, and as Chief Data Sciences Officer at Neumora. He has also held executive positions at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
Certara's CEO, William F. Feehery, PhD, expressed excitement about the appointment, emphasizing the value Dr. Reynders' expertise will bring to the company's ongoing development of transformational software and services for accelerating new medicines and increasing pharma R&D productivity.
Certara, Inc. (Nasdaq: CERT), leader mondiale nello sviluppo di farmaci informato da modelli, ha nominato John Reynders, PhD, nel suo Consiglio di Amministrazione, con effetto dal 15 ottobre 2024. Il Dr. Reynders porta con sé oltre 25 anni di esperienza nei settori farmaceutico e tecnologico, con competenze in intelligenza artificiale, scienza dei dati e scienze della vita.
I punti salienti della carriera del Dr. Reynders includono il ruolo di fondatore CIO di Moderna, dove ha guidato le capacità di scienza dei dati per la progettazione di terapie mRNA, e Chief Data Sciences Officer presso Neumora. Ha anche ricoperto posizioni dirigenziali in Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly e Celera.
Il CEO di Certara, William F. Feehery, PhD, ha espresso entusiasmo per la nomina, sottolineando il valore che l'esperienza del Dr. Reynders porterà nello sviluppo continuo di software e servizi trasformazionali dell'azienda per accelerare la creazione di nuovi medicinali e aumentare la produttività della R&D farmaceutica.
Certara, Inc. (Nasdaq: CERT), un líder mundial en el desarrollo de medicamentos informado por modelos, ha nombrado a John Reynders, PhD, en su Junta Directiva, con efecto a partir del 15 de octubre de 2024. El Dr. Reynders aporta más de 25 años de experiencia en las industrias farmacéutica y tecnológica, con experiencia en inteligencia artificial, ciencia de datos y ciencias de la vida.
Los aspectos más destacados de la carrera del Dr. Reynders incluyen su papel como CIO fundador de Moderna, donde dirigió las capacidades de ciencia de datos para el diseño de terapias de ARNm, y como Director de Ciencias de Datos en Neumora. También ha ocupado posiciones ejecutivas en Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly y Celera.
El CEO de Certara, William F. Feehery, PhD, expresó su entusiasmo por el nombramiento, enfatizando el valor que la experiencia del Dr. Reynders aportará al desarrollo continuo de software y servicios transformacionales de la compañía para acelerar la creación de nuevos medicamentos y aumentar la productividad de la I+D farmacéutica.
Certara, Inc. (Nasdaq: CERT), 모델 기반 약물 개발의 글로벌 리더,는 John Reynders, PhD를 이사회의 새로운 멤버로 임명하였으며, 이는 2024년 10월 15일부터 효력이 발생합니다. Dr. Reynders는 제약 및 기술 산업에서 25년 이상의 경험을 갖고 있으며, 인공지능, 데이터 과학, 생명 과학 분야에서 전문성을 가지고 있습니다.
Dr. Reynders의 경력 주요 내용에는 mRNA 치료 설계를 위한 데이터 과학 역량을 이끈 Moderna의 창립 CIO로 활동한 것과 Neumora의 데이터 과학 책임자 역할이 포함됩니다. 그는 또한 Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, Celera 등에서 임원직을 맡았습니다.
Certara의 CEO인 William F. Feehery, PhD는 이번 임명에 대한 기쁨을 표현하며 Dr. Reynders의 전문성이 회사의 혁신적인 소프트웨어 및 서비스 개발에 대한 가치가 큼을 강조했습니다. 이는 신약 개발을 가속화하고 제약 연구개발 생산성을 높이는 데 기여할 것입니다.
Certara, Inc. (Nasdaq: CERT), un leader mondial dans le développement de médicaments informé par des modèles, a nommé John Reynders, PhD, à son Conseil d'Administration, avec effet au 15 octobre 2024. Le Dr. Reynders possède plus de 25 ans d'expérience dans l'industrie pharmaceutique et technologique, avec une expertise en intelligence artificielle, science des données et sciences de la vie.
Parmi les points forts de la carrière du Dr. Reynders, on peut citer son rôle de CIO fondateur de Moderna, où il a dirigé les capacités de science des données pour la conception de thérapies ARNm, et celui de Chief Data Sciences Officer chez Neumora. Il a également occupé des postes de direction chez Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly et Celera.
Le PDG de Certara, William F. Feehery, PhD, a exprimé son enthousiasme concernant cette nomination, soulignant la valeur que l'expertise du Dr. Reynders apportera au développement continu de logiciels et de services transformationnels de l’entreprise pour accélérer la création de nouveaux médicaments et augmenter la productivité de la R&D pharmaceutique.
Certara, Inc. (Nasdaq: CERT), ein globaler Marktführer in der modellbasierten Arzneimittelentwicklung, hat John Reynders, PhD, in seinen Vorstand berufen, mit Wirkung zum 15. Oktober 2024. Dr. Reynders bringt über 25 Jahre Erfahrung in der Pharma- und Technologiebranche mit und verfügt über Expertise in künstlicher Intelligenz, Datenwissenschaft und Lebenswissenschaften.
Zu den Höhepunkten von Dr. Reynders' Karriere gehört die Tätigkeit als Gründung-CIO von Moderna, wo er die Data-Science-Fähigkeiten für das Design von mRNA-Therapien leitete, sowie die Position des Chief Data Sciences Officer bei Neumora. Er hat auch Führungspositionen bei Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly und Celera innegehabt.
Der CEO von Certara, William F. Feehery, PhD, äußerte seine Begeisterung über die Ernennung und betonte den Wert, den die Expertise von Dr. Reynders für die kontinuierliche Entwicklung von transformierenden Software- und Dienstleistungsangeboten zur Beschleunigung neuer Medikamente und zur Steigerung der Produktivität in der Pharma-F&E bringen wird.
- Appointment of John Reynders, PhD, an experienced pharmaceutical industry leader, to the Board of Directors
- Dr. Reynders brings expertise in artificial intelligence, data science, and life science
- Potential for enhanced development of transformational software and services in pharma R&D
- None.
RADNOR, Pa., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD, to its Board of Directors, effective October 15, 2024.
“We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “John’s expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&D.”
Dr. Reynders has over 25 years of experience in the pharmaceutical and tech industries. He was the founding CIO of Moderna where he led the data-sciences capabilities to design mRNA therapies. Most recently, he was Chief Data Sciences Officer at Neumora, a biotech focused on brain diseases. Before that, he held various executive positions leading data-sciences, informatics, and technology organizations at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera.
“I am pleased to join Certara’s Board of Directors and help build on their unique biosimulation portfolio, scientific expertise, and data assets. They are at the intersection of data and life sciences which is where I’ve spent most of my career,” said Dr. Reynders. “I look forward to working with the other board members and Certara’s leadership team to advance the Company’s next phase of growth.”
About Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
FAQ
Who is the new independent board member appointed by Certara (CERT)?
What is John Reynders' background and experience relevant to Certara (CERT)?
How might John Reynders' appointment benefit Certara (CERT)?
When did John Reynders join Certara's (CERT) Board of Directors?
